Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity? - PubMed - NCBI

Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity? - PubMed - NCBI

Cancer Invest. 2016 Oct 28:1-5. [Epub ahead of print]

Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?

Egloff H1, Jatoi A2.

Author information

Abstract

OBJECTIVE:

Few studies have examined toxicity from potentially curative chemotherapy in ovarian cancer patients at risk for breast cancer susceptibility (BRCA) mutation.

METHODS/RESULTS:

Ninety-four of the 482 patients appeared at risk for a mutation based on family history and 23 had a confirmed mutation. Hospitalization or emergency department visits were not increased based on family history with odds ratios (95% confidence intervals) of 0.88 (0.52, 1.45) (p =.62) and 0.90 (0.49, 1.58) (p =.71), respectively; similar findings were observed with confirmed mutations. Trends favored improved survival.

CONCLUSIONS:

Concern for a BRCA mutation should not preclude full dose chemotherapy in ovarian cancer patients treated with curative intent.

KEYWORDS:

Ovarian cancer; chemotherapy; treatment

PMID:

 

27791391

 

DOI:

 

10.1080/07357907.2016.1242011

[PubMed - as supplied by publisher]